Literature DB >> 24691745

Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries.

Ke-Qing Shi1, Fa-Ling Wu, Wen-Yue Liu, Chen-Chen Zhao, Chang-Xi Chen, Yao-Yao Xie, Sheng-Jie Wu, Xian-Feng Lin, Yong-Ping Chen, Danny Ka-Ho Wong, Man-Fung Yuen, Ming-Hua Zheng.   

Abstract

In-stent restenosis (ISR) remains the most common complication of percutaneous coronary intervention. Due to shared risk factors, it is postulated that non-alcoholic fatty liver disease (NAFLD) patients have an increased risk of ISR. This study aimed to determine the association between NAFLD and ISR in patients after bare metal stenting. This study included a cohort of 210 consecutive patients (150 men and 60 women) undergoing follow-up angiography. The primary end-point was angiographic ISR. Multivariate logistic regression analysis was used to identify independent risk factors for ISR. The cumulative ISR rate during follow-up was analyzed by Kaplan-Meier method. Subgroup analyses were also done for different gender. The ISR rate was 29.5%. Patients with NAFLD had a significantly higher prevalence of ISR than patients without NAFLD (43.3 vs. 16.0%, P < 0.001). In logistic regression analysis, NAFLD was associated with increased ISR, independent of low-density lipoprotein cholesterol, body mass index (adjusted odds ratio: 2.688, 95% confidence intervals: 1.285-5.537, P < 0.001). Male NAFLD patients had a higher prevalence of ISR than patients without NAFLD (48.4 vs. 15.3%, P < 0.001), while the prevalence of ISR in female patients with and without NAFLD were comparable (7.7 vs. 17.0%, P = 0.404). Kaplan-Meier analysis showed a significant association between NAFLD and ISR in all patients (log-rank P = 0.008) and in male subgroup (log-rank P = 0.033), but not in female subgroup (log-rank P = 0.313). This preliminary study suggests that NAFLD could independently associate with a high prevalence of ISR, especially in male patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691745     DOI: 10.1007/s11033-014-3342-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

Authors:  François R Jornayvaz; Varman T Samuel; Gerald I Shulman
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

3.  Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule.

Authors:  Takashi Kuwano; Shin-Ichiro Miura; Kazuyuki Shirai; Amane Ike; Ken Mori; Tomohiko Shimizu; Bo Zhang; Atsushi Iwata; Hiroaki Nishikawa; Akira Kawamura; Keijiro Saku
Journal:  J Atheroscler Thromb       Date:  2011-03-18       Impact factor: 4.928

4.  Obesity and clinical restenosis after coronary stent placement.

Authors:  Jamal S Rana; Murray A Mittleman; Kalon K Ho; Donald E Cutlip
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

Review 5.  Review: The role of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Kristina M Utzschneider; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

6.  Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury.

Authors:  Sophie J Bernelot Moens; Gavin R Schnitzler; Moriah Nickerson; Huiming Guo; Kazutaka Ueda; Qing Lu; Mark J Aronovitz; Heather Nickerson; Wendy E Baur; Ulla Hansen; Lakshmanan K Iyer; Richard H Karas
Journal:  Circulation       Date:  2012-09-20       Impact factor: 29.690

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus.

Authors:  Anuradhani Kasturiratne; Sanjaya Weerasinghe; Anuradha S Dassanayake; Shaman Rajindrajith; Arjuna P de Silva; Norihiro Kato; A Rajitha Wickremasinghe; H Janaka de Silva
Journal:  J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 4.029

9.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

10.  Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction.

Authors:  Cyrus V Desouza; Frederick G Hamel; Keshore Bidasee; Kelly O'Connell
Journal:  Diabetes       Date:  2011-02-23       Impact factor: 9.461

View more
  5 in total

Review 1.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

2.  Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention.

Authors:  Junfeng Liu; Yunde Liu; Kegang Jia; Zhixiao Huo; Qianyu Huo; Zhili Liu; Yongshu Li; Xuejing Han; Rong Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

3.  Predictive value of using plasma long non-coding RNAs ANRIL and HOXA11-AS for in-stent restenosis.

Authors:  Zhijiang Jin; Hongfeng Shen; Wei Cha; Haijiang Xia; Longbin Liu
Journal:  Exp Ther Med       Date:  2021-12-06       Impact factor: 2.447

Review 4.  Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

Authors:  Wah-Kheong Chan; Soek-Siam Tan; Siew-Pheng Chan; Yeong-Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva; Khean-Lee Goh; Anis Safura Ramli; Feisul Mustapha; Nik Ritza Kosai; Raja Affendi Raja Ali
Journal:  J Gastroenterol Hepatol       Date:  2022-02-08       Impact factor: 4.369

5.  Positive Association between APOA5 rs662799 Polymorphism and Coronary Heart Disease: A Case-Control Study and Meta-Analysis.

Authors:  Huadan Ye; Annan Zhou; Qiangxiao Hong; Linlin Tang; Xuting Xu; Yanfei Xin; Danjie Jiang; Dongjun Dai; Yirun Li; Dao Wen Wang; Shiwei Duan
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.